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ABSTRACT: The extract of microalga Nitzschia laevis (NLE) is considered a source of dietary fucoxanthin, a carotenoid
possessing a variety of health beneﬁts. In the present study, the bioaccessibility and deacetylation of fucoxanthin were studied by
simulated in vitro gastrointestinal digestion and colonic batch fermentation. In the gastric phase, higher fucoxanthin loss was
observed at pH 3 compared to pH 4 and 5. Lipases are crucial for the deacetylation of fucoxanthin into fucoxanthinol.
Fucoxanthinol production decreased signiﬁcantly in the order: pure fucoxanthin (25.3%) > NLE (21.3%) > fucoxanthin-
containing emulsion (11.74%). More than 32.7% of fucoxanthin and fucoxanthinol was bioaccessible after gastrointestinal
digestion of NLE. During colon fermentation of NLE, a higher loss of fucoxanthin and changes of short-chain fatty acid
production were observed but no fucoxanthinol was detected. Altogether, we provided novel insights on the fucoxanthin fate
along the human digestion tract and showed the potential of NLE as a promising source of fucoxanthin.
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■ INTRODUCTION
Fucoxanthin, accounting for 10% of total carotenoids in
nature,1 is an algal carotenoid. It possesses a variety of health-
beneﬁcial bioactivities: antioxidant, antidiabetes, anticarcino-
genic, antiallergic, anti-inﬂammatory, and antiosteoporotic
activities, among others.2 Particularly, both mice and human
studies have proven fucoxanthin eﬀective in reducing body
weight.3−5 Therefore, fucoxanthin-containing products are
now widely available on the market as functional food
supplements, predominantly indicated for weight loss.
Fucoxanthin is mainly found in brown algae (seaweeds) and
diatoms (microalgae). Most fucoxanthin-containing products
that are available are brown algae extracts supplemented with
oil and/or polyphenols from tea or other sources. However,
the fucoxanthin content in brown algae is much lower than
that of microalgae.6 Moreover, environmental issues, such as
land occupation, extraction technology, byproduct waste, and
contamination, are to be considered when dealing with
production of fucoxanthin from brown algae.7−9 Fucoxanthin
can be eﬀectively produced by microalgae: Fucovital, a
patented, all-natural 3% fucoxanthin oleoresin produced and
extracted from Phaeodactylum tricornutum, was granted New
Dietary Ingredient Notiﬁcation (NDIN, 1048, 2017) by the
U.S. Food and Drug Administration (FDA). Microalgae,
diatoms, speciﬁcally, have also been screened to produce
fucoxanthin.6 Among them, notably, Nitzschia laevis is a very
productive microalga, which was also successfully cultured
heterotrophically on glucose.10 The biomass concentration of
N. laevis in the fermenter could reach 17.25 g/L, and the
fucoxanthin productivity of mixed-cultured N. laevis could be
as high as 16.5 mg L−1 day−1, which is the highest reported for
diatoms up to now.11 Moreover, other functional ingredients,
including carotenoids (e.g., diadinoxanthin, diatoxanthin, β-
carotene, and lycopene), polyphenols, and lipids [especially
polyunsaturated fatty acids (PUFAs)], are usually present in
the extract of N. laevis.12 All of these make this extract a
potential sustainable source of fucoxanthin.
Bioavailability studies reported that most fucoxanthin is
absorbed as fucoxanthinol.13 A study on mice reported that
fucoxanthin was converted to fucoxanthinol in the gastro-
intestinal tract through deacetylation, possibly by lipase or
cholesterol esterase,13 and fucoxanthinol was then converted to
amarouciaxanthin by de-epoxidation in the liver in mice.14
Fucoxanthinol was detected in the liver, the lung, the spleen,
and the heart, while amarouciaxanthin was accumulated in the
adipose tissue.14 Human studies have been conducted with
fucoxanthin from brown algae, and both fucoxanthin and
fucoxanthinol have been detected in plasma.15 However, very
little is known about the behavior of fucoxanthin in the human
digestion tract and the factors aﬀecting its bioaccessibility and
conversion into fucoxanthinol from fucoxanthin-containing
products. In particular, fucoxanthin is easily oxidized in the
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presence of oxygen and is unstable in acidic conditions,16
indicating a possibility that fucoxanthin could be lost during
the gastric or small intestinal digestion. Also, diﬀerent
bioaccessibilities of fucoxanthin were observed for fucoxan-
thin-containing capsules and milk powder supplemented with
diﬀerent oils.17,18 Therefore, the inherent stability of
fucoxanthin and the interaction with other compounds (e.g.,
lipids) during digestion needs to be considered.
It is widely recognized that a substantial, if not predominant,
part of dietary carotenoids escapes absorption in the small
intestine and ends up in the colon, where they can shape gut
microbiota19 or gut metagenome.20 Speciﬁcally, the ability of
the fucoxanthin-containing extract of N. laevis to change the
gut microbiota composition when administered to mice for 2
months was reported.12 In addition, gut microbiota aﬀected
carotenoid bioavailability by altering the carotenoid absorption
or degradation patterns.21 A previous study reported that gut
microbiota may contribute to 11% of variance to the serum
xanthophyll concentration.22 However, how fucoxanthin
escaping absorption in the small intestine would interact
with gut microbiota, e.g., whether it is metabolized or not,
needs to be clariﬁed.
In the present study, fucoxanthin deacetylation and its
bioaccessibility from the extract of N. laevis were investigated
using simulated in vitro digestion models. The eﬀect of gastric
pH, kinetics of deacetylation, and bioaccessibility in the small
intestine were investigated. Moreover, fucoxanthin recovery
and the eﬀect on short-chain fatty acid (SCFA) production
were, for the ﬁrst time, analyzed through in vitro colonic
fermentation with human feces.
■ MATERIALS AND METHODS
Chemicals and Reagents. Pure fucoxanthin (PF, 16337),
porcine pepsin (P6887), porcine pancreatin (P1750, 4× USP),
porcine bile salt preparation (B8631), orlistat (04139), and butylated
hydroxytoluene (BHT) were purchased from Sigma-Aldrich (Merck
KGaA, Germany). Olive oil (extra virgin, Carapelli, Dallas, TX,
U.S.A.) was bought from a local market in the Netherlands. KCl,
KH2PO4, NaCl, MgCl2·(H2O)6, and CaCl2·(H2O)2, and pure ethanol
were purchased from VWR International B.V. (Netherlands).
KH2PO4, NaCl, (NH4)2CO3, NaOH, HCl, and Tween 80 were
purchased from Sigma-Aldrich Chemie B.V. (Netherlands) as well as
the yeast extract, peptone, mucine, and L-cysteine HCl. Acetonitrile
and chloroform were bought from LPS B.V. (Oss, Netherlands). All
of the chemicals used are of analytical and chromatographic grade.
Preparation of N. laevis Extract (NLE). The NLE was obtained
according to the method described in our previous paper.6 Brieﬂy,
about 100 mg of lyophilized powder was ground with liquid nitrogen.
Immediately, 10 mL of ethanol was added to the ground cells for
extraction, followed by end-to-end shaking for 1 h. Supernatants were
collected by centrifugation (2500g for 5 min at 4 °C). The extraction
was conducted twice, and the supernatants were combined. NLE was
obtained by evaporating with nitrogen at 22 °C. All of the procedures
were carried out under red light. The composition of NLE was
investigated in our previous study.12 The fucoxanthin content was
about 5.1%, and no fucoxanthinol is detected in the freshly extracted
NLE. Notably, there are more than 7% lipids in NLE.
Preparation of the Fucoxanthin-Containing Emulsion (FCE).
The FCE was prepared as previously described23 by mixing (13 500
rpm for 10 min, UltraTurrax, IKA-Werke, Staufen, Germany) pure
fucoxanthin and olive oil (5%, w/w) with an aqueous solution
containing Tween 80 (1%, w/w). The obtained FCE was stored at
−20 °C in the dark and used within 3 days.
Simulated In Vitro Gastrointestinal Digestion. All samples
were digested using a static in vitro digestion system consisting of a
simulated oral phase, gastric phase, and intestinal phase, with
modiﬁcations.24,25 The compositions (%, w/w) of the simulated
salivary ﬂuid (SSF), simulated gastric ﬂuid (SGF, pH 3.0 ± 0.05), and
simulated intestinal ﬂuid (SIF, pH 7.0 ± 0.05) were as reported.24
For the oral phase, for 5 mL samples (fucoxanthin content of 100
μg), 3.5 mL of SSF stock solution (37 °C), 25 μL of CaCl2 (0.3 M),
and 1.475 mL of Milli-Q water (Veolia water, Veolia Water Solutions
and Technologies Netherlands B.V.) were added and mixed. For the
experiment of oxidation prevention, 0.02 and 0.04% BHT were added.
Subsequently, to start the gastric phase, 5 mL of oral bolus was
mixed with 3.75 mL of SGF (37 °C). Then, 0.8 mL of porcine pepsin
stock solutions of 25 000 units/mL (2000 units/mL in ﬁnal chyme) in
SGF (37 °C) was added, followed by 2.5 μL of CaCl2 (0.3 M). Last,
about 0.1 mL of HCl (1 M) was added to reach pH 3. Finally, 0.349
mL of Milli-Q water was added to obtain the ﬁnal volume (10 mL).
Then, the chyme was shaken at 37 °C for 2 h without light. All
reactors were ﬁlled with nitrogen when closed before starting the
digestion. In the experiments at diﬀerent gastric pH, pH was adjusted
to 4 and 5 before starting the gastric phase with HCl.
At the end of the gastric digestion step, about 0.075 mL of NaOH
(1 M) was added to reach pH 7.0, inhibiting the gastric enzyme
activity. Thereafter, to 10 mL of gastric chyme, 5.5 mL of SIF (37
°C), 2.5 mL of porcine pancreatin (trypsin activity of 800 units/mL
and lipase activity of around 280 units/mg) in SIF (37 °C), 1.25 mL
of fresh bile stock solutions (10 mM in the ﬁnal intestinal chyme), 20
μL of CaCl2 (0.3 M), and 0.655 mL of Milli-Q water were added.
Finally, the chyme was incubated in a shaking water bath for 2 h at 37
°C, and the digestion was stopped by cooling immediately in an ice
bath. To study the kinetics of fucoxanthin micellarization, samples
were collected at 0, 10, 20, 30, 60, and 120 min, respectively. For the
inhibition of lipase activity, 10 μg/mL orlistat was added to pancreatin
dissolved in SSF and the mixture was incubated at 37 °C for 30 min
before undertaking the simulated pancreatic digestion.26 In this
experiment, samples were only collected after 120 min. Also, for the
experiment with BHT, samples were collected at the end of intestinal
digestion. All intestinal digests were centrifuged for 10 min at 20000g
(4 °C), and the supernatants were collected and ﬁltered through a
0.22 μm membrane ﬁlter (Phenomenex, Netherlands). Fucoxanthin
in the ﬁltered supernatants was supposed to have been incorporated
into the micellar phase. All tubes used here were ﬁlled with nitrogen
before starting the digestion procedure, and all procedures were
conducted under red light.
In Vitro Colonic Fermentation. Fresh fecal samples were
donated by three healthy adults [two Chinese and one Dutch, aged
23−28 years old, with a body mass index (BMI) of 18.5−23.9], who
declared no smoking and no antibiotic consumption for 6 months
before the beginning of the study. The fecal samples were prepared
according to protocols previously reported, with modiﬁcations.27,28
Brieﬂy, about 20.0 g of feces was diluted by 100 mL of anaerobic
phosphate buﬀer before homogenization in a stomacher bag. The
resulting fecal suspension was ﬁltered and considered as the fecal
microbiota inocula. The basal medium, consisting of 5.22 g/L
K2HPO4, 16.32 g/L KH2PO4, 2.0 g/L NaHCO3, 2.0 g/L yeast extract,
2.0 g/L peptone, 1.0 g/L mucine, 0.5 g/L L-cysteine HCl, and 2.0
mL/L tween 80, was used after 30 min ﬂushed with nitrogen before
autoclaving. Fucoxanthin (100 μg) from all fucoxanthin-containing
products dissolved in SIF was added, together with a 10% inoculation.
The fermentation was then started at 37 °C with continuous shaking
(60 rpm) under anaerobic conditions without light. In parallel, two
diﬀerent controls were conducted under the applied conditions: (i)
the fucoxanthin-containing fractions were fermented without
inoculation to determine possible chemical reactions, and (ii) the
fecal suspension was fermented without fucoxanthin-containing
products to be served as a negative control. All incubations were
performed in triplicate and sampled at 0, 2, 10, 24, 48, and 72 h. All of
the samples were centrifuged immediately when sampled, and the
supernatants were stored at −20 °C until use.
Fucoxanthin Analysis. For the in vitro gastrointestinal digestion
samples, fucoxanthin and its metabolites were extracted as previously
described,17 with tiny modiﬁcations. A total of 10 mL of digest was
mixed with 5 mL of chloroform as well as 0.5 g of NaCl, followed by
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end-to-end shaking for 30 min. Then, the chloroform layer was
collected through centrifugation (4700 rpm for 15 min at 4 °C). The
extraction was repeated twice, and both of the chloroform fractions
were combined. Chloroform was then evaporated with nitrogen, and
the samples were redissolved in ethanol before analysis with high-
performance liquid chromatography (HPLC). The same method was
applied to the supernatants in the batch fermentation experiments
(see the previous section).
Fucoxanthin was determined and quantiﬁed using a HPLC−diode
array detector (DAD) system (Ultimate 3000, Thermo Scientiﬁc,
Netherlands) equipped with an Onyx monolithic C18 column (100 ×
4.6 mm, with a pore size of 130 Å, Phenomenex, Netherlands). The
column temperature was kept at 30 °C. The mobile phase was a
mixture of acetonitrile and water (85:15), and the ﬂow rate was 1.5
mL/min. The injection volume was 10 μL. Fucoxanthin and
fucoxanthinol were identiﬁed at 450 nm and quantiﬁed using external
calibration curves.
The bioaccessibility/recovery of fucoxanthin was deﬁned as the
sum of fucoxanthin and fucoxanthinol contents that are detected in
the supernatants, divided by total fucoxanthin initially present in the
samples before digestion. Speciﬁc calculation was as follows:
=
+
×
C C
C
bioaccessibility/recovery (%)
100m,fucoxanthin m,fucoxanthinol
fucoxanthin
where Cm represents the fucoxanthin or fucoxanthinol amount in the
micellar phase and Cfucoxanthin represents the total fucoxanthin content
(μg) in the samples.
SCFA Analysis. Fecal-fermented samples (1 mL) were thawed and
centrifuged at 9000g for 5 min at 4 °C. The resulting supernatants
were then ﬁltered using a 0.2 μm RC ﬁlter. A total of 250 μL of
internal standard (0.45 mg/mL 2-ethylbutyic acid in 0.3 M HC and
0.9 M oxalic acid) was added to 500 μL of sample. Finally, the
solutions were mixed and centrifuged at 20000g for 4 min before
injection to gas chromatography (GC-2014, Shimadzu, Hertogen-
bosch, Netherlands), equipped with a capillary fatty-acid-free
Stabilwax-DA column (1 μm × 0.33 mm × 30 m, Restek, Bellefonte,
PA, U.S.A.), a ﬂame ionization detector, and a split injector. The
injection volume was 1.0 μL. The carrier gas was nitrogen, and the
temperatures of the injector and detector were 100 and 250 °C,
respectively. The temperature proﬁle starts with 100 °C, then
increased at 10.8 °C/min to 180 °C, and kept at 180 °C for 2 min.
Then, it increased at 50.00 °C/min until 240 °C and kept at 240 °C
for 2 min. Standard solutions of acetic, propionic, butyric, valeric,
isovaleric, and isobutyric acids in concentrations of 0.01−0.45 mg/mL
were prepared and used for identiﬁcation and quantiﬁcation.
Statistical Analysis. All of the data was expressed as the mean ±
standard deviation (SD). A Shapiro−Wilks test was used for the
evaluation of normality of distribution, and a Leven test was applied
for the equality of variance. One-way analysis of variance (ANOVA)
was performed using SPSS followed with Tukey test to evaluate
diﬀerences between groups. All ﬁgures were drawn with Origin 8.5
(OriginLab Corporation, Northampton, MA, U.S.A.). Statistical
signiﬁcance was set at p ≤ 0.05. All statistical analyses were performed
with SPSS 23.0 (SPSS, Chicago, IL, U.S.A.).
■ RESULTS AND DISCUSSION
Eﬀect of Gastric pH on the Recovery of Fucoxanthin.
The eﬀect of gastric pH on fucoxanthin recovery was tested,
and the results were shown in Figure 1. No signiﬁcant
diﬀerence for fucoxanthin bioaccessibility was observed when
PF and FCE were digested at pH 4 and 5 compared to pH 3.
However, gastric bioaccessibility of fucoxanthin from NLE was
signiﬁcantly lower at pH 3 compared to that of pH 4 and 5.
This last result agrees with previous results showing that
fucoxanthin exhibits the lowest stability at pH < 3, the highest
stability at pH 5−7, and intermediate stability in the pH range
of 3−5.16,29 Interestingly, a very limited amount of
fucoxanthinol was detected in all samples after gastric
digestion, indicating that the acidic environment of the
stomach contributes very little to the deacetylation of
fucoxanthin. However, because the fasted gastric pH is
typically around 2 and can increase up to 5 or above in the
fed state,30,31 consuming fucoxanthin after a meal might
preserve a higher fraction of fucoxanthin because of the higher
gastric pH.
Data in Figure 1 also showed that the gastric recovery of
fucoxanthin was about 40−70%, which means that more than
30% fucoxanthin was not detected. Carotenoid degradation in
acidic conditions is initiated by a largely unknown mecha-
nism.16 Some scholars have argued that carotenoids may be
degraded through protonation of the conjugated system in
acidic conditions.32 However, more complicated mechanisms
may account for the observed loss of fucoxanthin at acidic pH
because the allene and carboxyl groups were not detected after
acidic treatment.33 Also, we found that the gastric recovery of
fucoxanthin from NLE was much lower compared to that of
PF and FCE groups at pH 3. In this regard, other compounds
in NLE might aﬀect the recovery of fucoxanthin in this study.
Further investigation on fucoxanthin changes in acids is
needed. However, the observation that fucoxanthin could be
degraded during the gastric digestion is important when
developing fucoxanthin-based products.
Fucoxanthin Was Deacetylated into Fucoxanthinol
by Pancreatic Lipase. Previous studies suggest that
fucoxanthin is converted into fucoxanthinol by deacetylation
during digestion,34,35 but a systematic account of the
physiological factors modulating this transformation is still
missing. We hypothesized that pancreatic lipase may have a
primary role on the deacetylation of fucoxanthin to
fucoxanthinol because of its esterase activity. Also, pancreatic
Figure 1. Eﬀect of gastric pH on the recovery of fucoxanthin: (A) PF, (B) FCE, and (C) NLE. All of the data were from three replications and
expressed as the mean ± SD. In each panel, diﬀerent lowercase letters indicate statistical diﬀerences in recovery at p < 0.05.
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lipase is essential for lipid digestion and carotenoid
bioaccessibility by sustaining the formation of mixed micelles,
where carotenoids are incorporated. To test this hypothesis, we
run an additional in vitro intestinal digestion using orlistat, a
known inhibitor of pancreatic lipases, and a complete
inhibition was expected.26,36 Also, a further digestion was
carried out without pancreatin.
The results are shown in Figure 2. About 53% of initial
fucoxanthin was detected as fucoxanthinol after 2 h of
digestion with pancreatin, whereas only about 3% of initial
fucoxanthin was detected as fucoxanthinol after digestion with
orlistat and after digestion without pancreatin. Thus, we
concluded that pancreatic lipase mostly contributes to
fucoxanthin deacetylation in this simulated gastrointestinal
digestion. However, other digestive enzymes, such as carboxyl
ester lipase, phospholipase A2, and pancreatic lipase-related
proteins 1 and 2, possess esterase activity in the human small
intestine too. Because inhibition of these enzymes by orlistat is
also possible,37 we cannot exclude that they might also
contribute to fucoxanthin deacetylation in vivo.38 Moreover,
gastric lipase is produced in humans by chief cells of stomach
mucosa that might also contribute to fucoxanthin deacetylation
into fucoxanthinol in the gastric phase. This cannot be tested
at the moment in an in vitro digestion model because of the
lack of adequate replacers for human gastric lipase.
It is also worth noting that only 50−70% of initial
fucoxanthin was recovered in mixed micelles after intestinal
digestion, which is in line with previous reports that a partial
incorporation of carotenoids in mixed micelles is observed.39,40
We hypothesized that part of the loss may been ascribed to
oxidative degradation of fucoxanthin. Thus, a complete
simulated digestion (including both gastric and intestinal
phases) of PF was performed in the presence of 0.02 and
0.04% BHT (Figure 3); the addition of 0.04% BHT resulted in
a 30% increase in the ﬁnal fucoxanthin bioaccessibility. This
conﬁrms that part of the loss of fucoxanthin in the digestion
model and possibly in vivo is due to oxidation.
Bioaccessibility of Fucoxanthin and Deacetylation
Kinetics during Gastrointestinal Digestion. Bioaccessi-
bility of fucoxanthin and deacetylation kinetics in diﬀerent
formulations were studied by performing a complete (gastric +
intestinal) simulated digestion. Bioaccessibility values were
27.7, 27.5, and 32.7% for PF, FCE, and NLE, respectively
(Figure 4). This is pretty consistent with the loss observed
after individual gastric (Figure 1) and intestinal (Figure 2)
digestion. The kinetics of fucoxanthin deacetylation into
fucoxanthinol for diﬀerent samples is also illustrated in Figure
4. Overall, the total bioaccessibility (sum of fucoxanthin and
fucoxanthinol recovery) and the deacetylation degree were
clearly dependent upon the fucoxanthin source. At the
beginning of the intestinal digestion, the total bioaccessibility
is very high in FCE, intermediate in PF, and very low in NLE,
indicating diﬀerent gastric bioaccessibilities.
Speciﬁcally, in PF, fucoxanthinol was exponentially pro-
duced from fucoxanthin with concentrations (relative to the
initial fucoxanthin content) increasing from 6.7 to 25.3% at the
end of the intestinal digestion, while the fucoxanthin recovery
decreased from 14.8 to 2.4% (Figure 4A), indicating that most
fucoxanthin from PF samples was deacetylated into fucox-
anthinol.
In FCE, the same exponential trend for fucoxanthin
deacetylation was observed but less than half of fucoxanthin
that entered into the intestinal phase was converted to
fucoxanthinol, which is much less than that of the PF group
(Figure 4B). Because pancreatic lipase is involved in both
triglyceride hydrolysis and fucoxanthin deacetylation,25 we
hypothesize that lipid digestion and fucoxanthin deacetylation
might have competed with each other for lipase action. This
might have resulted in the smaller transformation of
fucoxanthin from FCE within the 60 min. Also, fucoxanthin
pre-emulsiﬁcation in FCE did not increase the bioaccessibility
of fucoxanthin compared to that of PF, which seems to
contradict studies indicating that emulsiﬁcation assists
carotenoid bioaccessibility, primarily by providing lipids for
micellaration.41 However, lipids should be digested into free
fatty acids and monoacylglycerides before being incorporated
into mixed micelles.39 In this respect, the competition for
lipase might also have resulted in less micellarization, which
might have reduced the total bioaccessibility of fucoxanthin
from FCE.
In NLE, within 20 min, both fucoxanthin and fucoxanthinol
contents in the intestinal supernatant increased. Afterward,
fucoxanthinol was continuously produced, while fucoxanthin
content began to fall down until the end of the intestinal phase
(Figure 4C). The ﬁnal fucoxanthin and fucoxanthinol
bioaccessibilities were 11.4 and 21.3%, respectively, indicating
that about 2/3 of fucoxanthin that entered into the small
intestine was converted into fucoxanthinol, which is higher
than that of FCE and lower than that of PF. Also, the total
bioaccessibility of NLE fucoxanthin gradually but signiﬁcantly
Figure 2. Eﬀect of pancreatic lipase on the deacetylation of
fucoxanthin during simulated in vitro intestinal digestion. Data are
expressed as a percentage of the initial amount. All of the data were
from three replications and expressed as the mean ± SD. P, intestinal
digestion with pancreatin; P + O, intestinal digestion with pancreatin
and orlistat; and −P, intestinal digestion without pancreatin.
Figure 3. Eﬀect of diﬀerent concentrations of BHT on bioaccessibility
of fucoxanthin during simulated in vitro intestinal digestion. All of the
data were from three replications and expressed as the mean ± SD.
Diﬀerent lowercase letters indicate statistical diﬀerences in bioacces-
sibility at p < 0.05.
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increased during the intestinal digestion, and a higher
bioaccessibility was obtained in comparison to that of PF
and FCE at the end of intestinal digestion. In comparison to
PF and FCE, NLE composition is more complex; i.e., other
compounds are present that might have aﬀected the
deacetylation and promoted its bioaccessibility in the present
study. However, speciﬁc mechanisms are unclear and need to
be further studied.
Fucoxanthin Recovery during In Vitro Colonic
Fermentation. NLE was added in the in vitro batch
fermentation model with human feces, and the recovery of
fucoxanthin was shown in Figure 5. A control was added,
where NLE was simply dissolved in the fermentation ﬂuids
without microbiota. Notably, loss of fucoxanthin from all
treated groups and the control was observed. However, in
comparison to the control, signiﬁcant lower concentrations of
fucoxanthin at times of <10 h were observed when microbiota
was present, suggesting that fucoxanthin might be metabo-
lized/used by human microbiota. After 24 h, fucoxanthin
recovery from NLE reached a level comparable to that of the
control group (Figure 5), which remained substantially
unchanged until the end of the fermentation for microbiota
from donors 1 and 2. With microbiota from donor 3,
fucoxanthin recovery continued to decrease until the end of
fermentation (Figure 5). Surprisingly, however, no fucoxan-
thinol was produced during the 72 h fermentation for all
groups, indicating possibilities that either no fucoxanthin was
deacetylated by the microbiota or a further, rapid metabolism
of fucoxanthinol into other compounds (Figure S1 of the
Supporting Information). In general, there is a paucity of
information on carotenoid metabolism by gut microbiota,
especially for fucoxanthin. These data represent the ﬁrst report
on the fate of fucoxanthin in the colon phase. Because some
absorption of carotenoids in the colon is likely,42 the loss of
fucoxanthin credited to gut microbiota may aﬀect its overall
bioavailability.
Eﬀect of Fucoxanthin on SCFA Production during In
Vitro Colonic Fermentation. In the present study, we have
investigated whether the presence of dietary fucoxanthin would
aﬀect the fermentative activity of gut microbiota from three
diﬀerent donors by measuring the SCFA concentration during
fermentation of a basal medium with and without the addition
of NLE (Figure 6). SCFA levels were diﬀerent among the three
donors. SCFAs produced by microbiota of donor 3 were much
higher than those of donors 1 and 2. No signiﬁcant changes
were observed when NLE was added to microbiota from donor
1. However, SCFA production was greatly reduced when NLE
Figure 4. Bioaccessibility of fucoxanthin and deacetylation kinetics during simulated in vitro gastrointestinal digestion. The time course of
fucoxanthin bioaccessibility is reported in the bar chart: (A) PF, (B) FCE, and (C) NLE. The column is the sum of fucoxanthin and fucoxanthinol
contents. The lines indicated the fucoxanthin deacetylation: the orange line indicates the percentage of fucoxanthin, and the green line indicates the
percentage of fucoxanthinol. All of the data were from three replications and expressed as the mean ± SD. Diﬀerent lowercase letters indicate a
signiﬁcant diﬀerence (p < 0.05) in fucoxanthin bioaccessibility.
Figure 5. Fucoxanthin recoveries from the fermented supernatants
during the in vitro colon fermentation. C represents fermentation of a
basal medium with the addition of NLE but without microbiota
inoculation. D1, D2, and D3 represent fermentation of the basal
medium with the addition of NLE to microbiota of donors 1, 2, and 3,
respectively. All of the data were from three replications and expressed
as the mean ± SD. Diﬀerent lowercase letters indicate statistical
diﬀerence (p < 0.05) in the fucoxanthin content compared to the
control at a speciﬁc time point.
Figure 6. SCFA production after 72 h of in vitro colonic fermentation.
All of the data were from three replications and expressed as the mean
± SD. C1, C2, and C3 represent fermentation of a basal medium
without the addition of NLE to microbiota of donors 1, 2, and 3,
respectively. D1, D2, and D3 represent fermentation of the basal
medium with the addition of NLE to microbiota of donors 1, 2, and 3,
respectively.
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was fermented by microbiota of donors 2 and 3. Speciﬁcally,
acetic acid production was reduced in donors 2 and 3 but not
with microbiota of donor 1. For all three treated groups,
propionic acid levels were not diﬀerent compared to their
controls. Butyric acid production was reduced by NLE
addition in donors 2 and 3 but not in donor 1. All three
SCFAs, acetic, propionic, and butyric acids, represent 90−95%
of the total SCFAs present in the colon. These SCFAs are not
only crucial for gut health but might also directly aﬀect the
metabolism or the function of peripheral tissues when
absorbed by the host.43 Also, SCFA production depends
upon microbiota strains, and these SCFA-produced strains
could be manipulated by diet.44 In this sense, the changes of
SCFA production might indicate a modulation of microbiota
by NLE.
In the current study, for the ﬁrst time, we reported a
systematic investigation of fucoxanthin deacetylation and
bioaccessibility during gastrointestinal digestion and colonic
fermentation. A higher recovery of fucoxanthin (in the form of
fucoxanthin and fucoxanthinol) from NLE was observed in
comparison to that from PF and FCE. Also, we provide
evidence that fucoxanthin transformation into fucoxanthinol is
mostly carried out by digestive lipases, most likely and
primarily by pancreatic lipase, and that fucoxanthinol
production follows exponential kinetics during digestion.
More than 50% of fucoxanthin was lost after 24 h of
fermentation by gut microbiota in part because of the
metabolism of fucoxanthin by the gut microbiota. However,
the nature and fate of fucoxanthin metabolites are still
unknown and require further investigation. Similarly, bio-
accessibility of fucoxanthin from common food preparations
based on algae is warranted to probe the actual bioaccessibility
of fucoxanthin from these sources.
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